Cost-effectiveness of strontium ranelate in the treatment of male osteoporosis

Osteoporosis International

Volumn 24, Issue 8, 2013, Pages 2291-2300

  Hiligsmann, M ^a,b   Ben Sedrine, W ^b   Bruyere O ^b   Reginster, J Y ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Cost effectiveness; Fractures; Men; Osteoporosis; Strontium ranelate

Indexed keywords

STRONTIUM RANELATE;

AGED; ARTICLE; BONE DENSITY; COST EFFECTIVENESS ANALYSIS; FEMALE; FEMUR NECK; HUMAN; INTENTION TO TREAT ANALYSIS; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR; RISK REDUCTION; SPINE FRACTURE;

AGED; BELGIUM; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; FEMUR NECK; HEALTH CARE COSTS; HUMANS; INCIDENCE; LUMBAR VERTEBRAE; MALE; MODELS, ECONOMETRIC; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; QUALITY-ADJUSTED LIFE YEARS; THIOPHENES;

EID: 84880266528     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-013-2272-2     Document Type: Article

References (64)

1. Ringe JD (2010) Osteoporosis in men. Medicographia 32:71-8
2. Hiligsmann M, Bruyere O, Roberfroid R, et al. (2011) Trends in hip fracture incidence and in the prescription of anti-osteoporosis medications in Belgium (2000-2007). Arthritis Care Res (Hoboken) 2012;64:744-50
3. Kanis JA, Johnell O, Oden A et al (2000) Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 11:669-74
4. Haentjens P, Magaziner J, Colon-Emeric CS et al (2010) Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 152:380-90
5. Meunier PJ, Roux C, Seeman E et al (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459-68
6. Reginster JY, Felsenberg D, Boonen S et al (2008) Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum 58:1687-95
7. Reginster JY, Seeman E, De Vernejoul MC et al (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90:2816-22
8. Seeman E, Devogelaer JP, Lorenc R et al (2008) Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia. J Bone Miner Res 23:433-8
9. Reginster JY, Kaufman JM, Goemaere S et al (2012) Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis. Osteoporosis Int 23:1115-22
10. Borgstrom F, Jonsson B, Strom O, Kanis JA (2006) An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials. Osteoporos Int 17:1781-93
11. Borgstrom F, Strom O, Coelho J et al (2010) The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis. Osteoporos Int 21:339-49
12. Hiligsmann M, Bruyere O, Reginster JY (2010) Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years. Bone 46:440-6
13. Hiligsmann M, Bruyere O, Reginster JY (2010) Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women. Osteoporos Int 21:157-65
14. Hiligsmann M, Vanoverberghe M, Neuprez A, Bruyere O, Reginster JY (2010) Cost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis. Expert Rev Pharmacoecon Outcomes Res 10:359-66
15. Kaufman JM, Audran M, Bianchi G, et al. (2011) Efficacy and safety of strontium ranelate in the treatment of male osteoporosis. Ann Rheum Dis EULAR 11-4358
16. Taylor RS, Drummond MF, Salkeld G, Sullivan SD (2004) Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. BMJ 329:972-5
17. Drummond M, Dubois D, Garattini L et al (1999) Current trends in the use of pharmacoeconomics and outcomes research in europe. Value Health 2:323-32
18. Hiligsmann M, Ethgen O, Bruyere O, Richy F, Gathon HJ, Reginster JY (2009) Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis. Value Health 12:687-96
19. Hiligsmann M, Gathon HJ, Bruyere O, Ethgen O, Rabenda V, Reginster JY (2010) Cost-effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence. Value Health 13:394-401
20. Hiligsmann M, Rabenda V, Bruyere O, Reginster JY (2010) The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy 96:170-7
21. Hiligsmann M, Rabenda V, Gathon HJ, Ethgen O, Reginster JY (2010) Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int 86:202-10
22. Hiligsmann M, Reginster JY (2010) Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women. Bone 47:34-40
23. Hiligsmann M, Reginster JY (2011) Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in belgium. PharmacoEconomics 29:895-911
24. Johansson H, Kanis JA, McCloskey EV et al (2011) A FRAX(R) model for the assessment of fracture probability in Belgium. Osteoporos Int 22:453-61
25. Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12:417-27
26. Johnell O, Kanis JA, Oden A et al (2004) Mortality after osteoporotic fractures. Osteoporos Int 15:38-42
27. Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B (2004) Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 15:108-12
28. Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone 32:468-73
29. Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D (2000) Risk of mortality following clinical fractures. Osteoporos Int 11:556-61
30. Tosteson AN, Jonsson B, Grima DT, O'Brien BJ, Black DM, Adachi JD (2001) Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporos Int 12:849-57
31. Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B (2004) Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 15:108-12
32. Cleemput I, van Wilder P, Huybrechts M, Vrijens F (2009) Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests. Value Health 12:441-49
33. Hiligsmann M, Gathon HJ, Bruyere O et al (2011) Hospitalisation costs of hip fractures in Belgium. Osteoporos Int 22:332, Abstract, 11th ECCEO-IOF
34. Autier P, Haentjens P, Bentin J et al (2000) Costs induced by hip fractures: a prospective controlled study in Belgium. Belgian Hip Fracture Study Group. Osteoporos Int 11:373-80
35. Reginster JY, Gillet P, Ben Sedrine W et al (1999) Direct costs of hip fractures in patients over 60 years of age in Belgium. PharmacoEconomics 15:507-14
36. Melton LJ 3rd, Gabriel SE, Crowson CS, Tosteson AN, Johnell O, Kanis JA (2003) Cost-equivalence of different osteoporotic fractures. Osteoporos Int 14:383-8
37. Hiligsmann M, Ethgen O, Richy F, Reginster JY (2008) Utility values associated with osteoporotic fracture: a systematic review of the literature. Calcif Tissue Int 82:288-92
38. Tosteson AN, Gabriel SE, Grove MR, Moncur MM, Kneeland TS, Melton LJ 3rd (2001) Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporos Int 12:1042-9
39. Looker AC, Wahner HW, Dunn WL et al (1998) Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 8:468-89
40. Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254-9
41. Johnell O, Kanis JA, Oden A et al (2005) Predictive value of BMD for hip and other fractures. J Bone Miner Res 20:1185-94
42. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721-39
43. Kanis JA, Johnell O, De Laet C et al (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375-82
44. Bruyere O, Roux C, Badurski J et al (2007) Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranelate. Curr Med Res Opin 23:3041-5
45. Bruyere O, Roux C, Detilleux J et al (2007) Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab 92:3076-81
46. Meunier PJ, Roux C, Ortolani S et al (2009) Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporos Int 20:1663-73
47. Rabenda V, Mertens R, Fabri V et al (2008) Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 19:811-8
48. Belgian Centre for Pharmacotherapeutic Information, 2011, Available at: http://www.cbip.be/GGR/MPG/MPG-NJ.cfm#MP-2583 [Accessed 1 July 2011].
49. Borgstrom F, Strom O, Kleman M et al (2011) Cost-effectiveness of bazedoxifene incorporating the FRAX(R) algorithm in a European perspective. Osteoporos Int 22:955-65
50. Kanis JA, Borgstrom F, Johnell O, Oden A, Sykes D, Jonsson B (2005) Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporos Int 16:15-25
51. Haentjens P, De Groote K, Annemans L (2004) Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis. Arch Orthop Trauma Surg 124:507-17
52. Cleemput I, Neyt M, Thiry N, et al. Valeurs seuils pour le rapport coût-efficacité en soins de santé. Health Technology Assessment (HTA). Bruxelles: Centre fédéral d'expertise des soins de santé (KCE);2008. KCE Reports 100B (D/2008/10.273/95). 2008.
53. Ebeling PR (2008) Clinical practice. Osteoporosis in men. N Engl J Med 358:1474-82
54. Borgstrom F, Johnell O, Jonsson B, Zethraeus N, Sen SS (2004) Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden. Bone 34:1064-71
55. Kanis JA, Johnell O, Oden A et al (2005) Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden. Osteoporos Int 16:6-14
56. Roux C, Reginster JY, Fechtenbaum J et al (2006) Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res 21:536-42
57. Kanis JA, Johansson H, Oden A, McCloskey EV (2011) A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX((R)). Osteoporos Int 22:2347-55
58. Rabenda V, Hiligsmann M, Reginster J-Y (2009) Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence. Expert Opin Pharmacother 10:2303-15
59. Kanis JA, Cooper C, Hiligsmann M, Rabenda V, Reginster JY, Rizzoli R (2011) Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporos Int 22:2565-73
60. Borgstrom F, Kanis JA (2008) Health economics of osteoporosis. Best Pract Res Clin Endocrinol Metab 22:885-900
61. Adachi JD, Ioannidis G, Pickard L et al (2003) The association between osteoporotic fractures and health-related quality of life as measured by the Health Utilities Index in the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int 14:895-904
62. Papaioannou A, Kennedy CC, Ioannidis G et al (2009) The impact of incident fractures on health-related quality of life: 5 years of data from the Canadian Multicentre Osteoporosis Study. Osteoporos Int 20:703-14
63. Goz V, Koehler SM, Egorova NN et al (2011) Kyphoplasty and vertebroplasty: trends in use in ambulatory and inpatient settings. Spine J 11:737-44
64. Drummond M, Barbieri M, Cook J et al (2009) Transferability of economic evaluations across jurisdictions: ISPOR good research practices task force report. Value Health 12:409-18